Selank

Selank is a synthetic peptide developed in Russia and marketed online as an anti-anxiety and “nootropic” compound. The human evidence is real but thin, almost entirely Russian, and small in scale.

What it is

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, a naturally occurring immune-signaling fragment of immunoglobulin G. Researchers at Russia’s Institute of Molecular Genetics added a stabilizing fragment to tuftsin to extend its half-life. It is typically administered as an intranasal solution. In Russia it is sold as a prescription nasal spray.

The claims

Vendors and clinics promote Selank for generalized anxiety, stress, “benzodiazepine-level” calm without sedation or dependence, sharper focus, better mood, and immune modulation. Some sites also claim antidepressant and neuroprotective effects.

What the evidence actually shows

Human data exist, which is more than can be said for many peptides sold online, but the studies are small, mostly open-label or add-on designs, short in duration, and conducted by a small number of Russian groups. A comparison in 62 patients with generalized anxiety disorder and neurasthenia reported anxiolytic effects broadly similar to the benzodiazepine medazepam, with additional anti-fatigue effects. A 2015 trial in 70 patients found that adding Selank to the benzodiazepine phenazepam reduced side effects while preserving benefit. A 2008 study reported shifts in immune cytokine markers in patients with anxiety-asthenic disorders.

These are genuine human signals, but none are large, placebo-controlled, independently replicated Western trials, and full texts are often available only in Russian. Most other published work is in rats and mice (morphine withdrawal, alcohol-induced memory deficits, stress models) or in cell lines. Notably, a 2017 cell-culture study often cited as a mechanistic basis actually found that Selank had no direct effect on the expression of GABA-related genes, so the precise mechanism remains unsettled. The popular “as good as a benzodiazepine, with none of the downsides” framing outruns what this evidence can support.

Legal and regulatory status

Selank was approved by Russia’s Ministry of Health around 2009 and is available there by prescription as a 0.15% intranasal spray for generalized anxiety disorder. It is not approved by the US FDA or by European regulators, and it is not an approved drug in most Western countries. It is not a dietary supplement; in the US it is sold only as a “research chemical” labeled not for human consumption, which places it outside any framework for verified identity, purity, or dosing.

One caveat on the US picture: in 2026, HHS and the FDA signaled an intent to ease compounding restrictions on a group of peptides, with Selank among those reportedly under consideration. As of this writing that process is not finalized; it remains under FDA advisory-committee review and would, at most, allow compounding pharmacies to prepare the peptide by prescription. It would not constitute FDA approval, which requires completed clinical trials for a specific indication.

For athletes: Selank is not named on the World Anti-Doping Agency Prohibited List. WADA’s S0 category covers substances with no current approval by any governmental health authority for human therapeutic use. Because Selank does hold a Russian approval, its S0 status is genuinely ambiguous rather than clear-cut. That ambiguity is itself a reason for caution: any athlete subject to testing should confirm status with their sport’s anti-doping authority before use.

Safety

Short Russian trials describe Selank as well tolerated, with few reported adverse effects and no clear dependence or withdrawal of the kind seen with benzodiazepines. But this reassurance rests on small, short studies. There are no long-term safety data, no large safety databases, and no good information on interactions or use in pregnancy. Product sold as a “research chemical” carries the added, unquantified risk of contamination or mislabeling.

Bottom line

Selank is one of the better-studied “nootropic” peptides, with approval and clinical use in Russia and real human trials behind it. But by Western standards the evidence is preliminary: small, short, single-country, and largely uncontrolled, with no FDA approval and no long-term safety data. Promising is not the same as proven. None of this is medical advice.

Evidence grade: Preliminary human.

Sources

• Optimization of the treatment of anxiety disorders with selank (RCT, n=70). Zh Nevrol Psikhiatr Im S S Korsakova, 2015
• Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova, 2008
• Zozulya AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (selank vs medazepam, n=62), 2008
• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol, 2017
• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol, 2017
• WADA Prohibited List (category S0, non-approved substances)
• FDA moves toward easing restrictions on certain peptides. BioPharma Dive, 2026